Hologic, Inc. (NASDAQ:HOLX) Receives $78.75 Consensus PT from Brokerages

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) has received a consensus recommendation of "Hold" from the seventeen brokerages that are presently covering the firm, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $78.75.

Several research firms recently commented on HOLX. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $60.00 to $80.00 in a research note on Wednesday. Morgan Stanley lowered their price objective on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Finally, Stephens lowered their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th.

Insider Activity at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director owned 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.88% of the company's stock.

Hedge Funds Weigh In On Hologic

Several institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its holdings in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Beverly Hills Private Wealth LLC grew its holdings in Hologic by 3.6% in the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after buying an additional 180 shares in the last quarter. Allworth Financial LP grew its holdings in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after buying an additional 216 shares in the last quarter. Dark Forest Capital Management LP grew its holdings in Hologic by 7.9% in the 4th quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after buying an additional 223 shares in the last quarter. Finally, Baker Avenue Asset Management LP grew its holdings in Hologic by 0.5% in the 4th quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after buying an additional 225 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Stock Down 1.3%

Shares of NASDAQ:HOLX traded down $0.90 during trading on Thursday, hitting $65.95. The company's stock had a trading volume of 700,429 shares, compared to its average volume of 2,380,792. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. Hologic has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The stock's 50-day moving average price is $61.32 and its two-hundred day moving average price is $63.59. The company has a market capitalization of $14.70 billion, a PE ratio of 27.77, a PEG ratio of 2.41 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the previous year, the firm posted $1.03 earnings per share. The company's revenue was down 1.2% compared to the same quarter last year. As a group, sell-side analysts expect that Hologic will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.